Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation
Publication Type:
Journal Article
Authors:
Forns, X.;
M R Charlton;
Denning, J.;
J G McHutchison;
Symonds, W.T.;
Brainard, D.;
Brandt-Sarif, T.;
Chang, P.;
Kivett, V.;
Castells, L.;
Prieto, M.;
Robert J Fontana;
Baumert, T.F.;
Coilly, A.;
Londono, M.C.;
Habersetzer, F.Source:
Hepatology, Volume 61, Issue 5, p.1485-1494 (2015)
Keywords:
analogs & derivatives,
analysis,
Antiviral Agents,
clinical trial,
Compassionate Use Trials,
Death,
Disease,
Drug Interactions,
drug therapy,
Female,
HCV,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hepatitis C,Chronic,
Humans,
Infection,
interferon,
Life,
Life Expectancy,
Liver,
Liver Transplantation,
Male,
Middle Aged,
Patients,
pegylated,
pegylated interferon,
PROVIDE,
Recurrence,
Research,
Research Support,
Ribavirin,
Severity of Illness Index,
sofosbuvir,
Spain,
surgery,
SVR,
therapeutic use,
transplantation,
treatment,
Treatment Failure,
Universities,
Uridine,
Uridine Monophosphate
